eISSN: 2720-5371
ISSN: 1230-2813
Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii
Current issue Archive Manuscripts accepted About the journal Scientific board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2019
vol. 28
 
Share:
Share:
abstract:
Review paper

Clozapine-induced myocarditis

Piotr Jahołkowski
1, 2
,
Paweł Mierzejewski
2
,
Piotr Świtaj
1

  1. 1st Department of Psychiatry, Institute of Psychiatry and Neurology, Warsaw, Poland
  2. Department of Pharmacology and Physiology of the Nervous System, Institute of Psychiatry and Neurology, Warsaw, Poland
Adv Psychiatry Neurol 2019; 28 (1): 54-69
Online publish date: 2018/12/28
View full text Get citation
 
PlumX metrics:
Purpose
Presentation of the current state of knowledge on the epidemiology, pathogenesis, clinical picture, diagnosis and treatment of clozapine-induced myocarditis (CIM).

Views
Clozapine is widely used in patients with psychotic disorders for whom previous therapy was inadequate or not tolerated. However, in some cases its use may be associated with serious side-effects. In addition to agranulocytosis, ketoacidosis and intestinal obstruction, CIM is the most serious and potentially life-threatening complication of clozapine therapy, as it encompasses the inflammation and injury of the heart muscle. Attempts to estimate the incidence of CIM are characterized by a large discrepancy of results. To date, the pathomechanism of CIM has not been well investigated. The variability of the clinical spectrum and the lack of pathognomonic signs significantly hinder diagnosis, which is usually based on clinical symptoms, echocardiography, concentration of troponin and C-reactive protein in the serum samples and, in some cases, by myocardial biopsy and cardiac magnetic resonance imaging. In patients with suspected/confirmed CIM, the main recommendation is to discontinue clozapine and monitor the patient’s vital signs. Clinical observations indicate that a β-blocker and/or angiotensin-converting enzyme inhibitor might be useful in at least same cases of CIM.

Conclusions
We point out that patients receiving clozapine should be carefully monitored for the symptoms of CIM. The publication contains guidelines for dealing with suspected CIM.

keywords:

C-reactive protein, clozapine, myocarditis, troponin

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.